Reata Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Reata Pharmaceuticals, Inc.
With its multiple sclerosis legacy under various pressures but four new drugs in indications outside of MS, the company expects flat product revenue in 2024 after a 3.8% decline in 2023.
Friedreich’s ataxia is particularly prevalent in Europe, and the company hopes to replicate the fast US uptake for Skyclarys there.
Priya Singhal, head of development, spoke with Scrip about the company’s R&D restructuring, readouts coming from the culled pipeline and how Biogen is thinking about adding to it in the future.
Innovation metrics like first-in-class and breakthrough therapy approvals declined as a share of novel agents in 2023, even as the US FDA’s drugs center posted one of its biggest novel approval totals ever.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.